Neuropathic Pain, Pain Due to Certain Specified Procedures
Conditions
Keywords
neuropathic pain due to thoracotomy, Neuropathic Pain Due to Thoracoscopy
Brief summary
Botulinum toxin type A has been reported to inhibit the release of various pain neurotransmitters (SP, CGRP, glutamate) responsible for neurogenic inflammation, a process that results from the sensitization of C-fiber nociceptors (peripheral sensitization). This action is probably responsible for the analgesic effect of botulinum toxin type A recently demonstrated in patients with neuropathic pain of peripheral origin.In those studies, patients had been suffering for years. The investigators can hypothesizes that earlier administration of Botox in the course of neuropathic pain might prevent central sensitization, that is secondary to peripheral sensitization. The investigators can hope to increase efficacy of Botulinum toxin type A injections and to prevent chronification of pain.
Interventions
DRUGBOTOX
A syringe of 1 ml contain 25 Allergan units.
OTHERPLACEBO
The pharmacist will fill syringes in tuberculins of 1 ml with injectable solution of sodium chloride of 0,9 %.
Sponsors
University Hospital, Limoges
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* daily pain, for 3 months, secondary to thoracoscopy or thoracotomy, of neuropathic origin (DN4 questionary)
Exclusion criteria
* contraindications for botulinum toxin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| decrease in average pain intensity as measured by the Brief Pain Inventory (BPI) | one month |
Secondary
| Measure | Time frame |
|---|---|
| VAS in the last 24 hours | 24 hours |
| Neuropathic Pain Inventory | 6 months |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORDanièle RANOUX, MD
University Hospital, Limoges
Outcome results
None listed